← Evidence map

ArticleTranslational oncology2026

Combined treatment of TROP‑2 targeted CAR-T and vascular disruptor CBP enhances anti‑tumor activity in triple‑negative breast cancer.

Yizhu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Combined treatment of TROP‑2 targeted CAR-T and vascular disruptor CBP enhances anti‑tumor activity in triple‑negative breast cancer. | Socratic